{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:45:25Z","timestamp":1789123525651,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,21]]},"DOI":"10.7759\/cureus.102018","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T23:56:57Z","timestamp":1769039817000},"source":"Crossref","is-referenced-by-count":4,"title":["Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Marwan","family":"Tantoush","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaseen","family":"Almaghrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allaeddin","family":"Abusbaeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouraddeen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoub","family":"Tantush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaeddin","family":"Ben Hamida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Sagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motasem","family":"Sager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aly","family":"Abouslima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E","family":"Elbahnasawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M","family":"Elhady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hesham Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun H","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, et al.. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022, 183:109119. 10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"key":"ref2","unstructured":"World Health Organization (WHO). Diabetes. (2024). Accessed: November 24, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1797-8","article-title":"The integrative biology of type 2 diabetes","volume":"576","author":"Roden M","year":"2019","unstructured":"Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019, 576:51-60. 10.1038\/s41586-019-1797-8","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.7.1599","article-title":"Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002","volume":"28","author":"Sullivan PW","year":"2005","unstructured":"Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR, Hill JO. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care. 2005, 28:1599-1603. 10.2337\/diacare.28.7.1599","journal-title":"Diabetes Care"},{"key":"ref5","unstructured":"World Health Organization (WHO). Obesity and overweight. (2025). Accessed: November 24, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03095-3","article-title":"A new framework for the diagnosis, staging and management of obesity in adults","volume":"30","author":"Busetto L","year":"2024","unstructured":"Busetto L, Dicker D, Fr\u00fchbeck G, Halford JC, Sbraccia P, Yumuk V, Goossens GH. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med. 2024, 30:2395-2399. 10.1038\/s41591-024-03095-3","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.04","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald E","year":"2022","unstructured":"Grunvald E, Shah R, Hernaez R, et al.. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022, 163:1198-1225. 10.1053\/j.gastro.2022.08.04","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey WT","year":"2016","unstructured":"Garvey WT, Mechanick JI, Brett EM, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016, 22:1-203. 10.4158\/EP161365.GL","journal-title":"Endocr Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck MA","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021, 46:101102. 10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng Z","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024, 9:234. 10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton S","year":"2025","unstructured":"Wharton S, Aronne LJ, Stefanski A, et al.. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025, 393:1796-1806. 10.1056\/NEJMoa2511774","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer X","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al.. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015, 373:11-22. 10.1056\/NEJMoa1411892","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-021-01000-w","article-title":"Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery","volume":"12","author":"Lewis AL","year":"2022","unstructured":"Lewis AL, McEntee N, Holland J, Patel A. Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery. Drug Deliv Transl Res. 2022, 12:1-6. 10.1007\/s13346-021-01000-w","journal-title":"Drug Deliv Transl Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda VR","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, et al.. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019, 42:1724-1732. 10.2337\/dc19-0749","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias JP","year":"2023","unstructured":"Frias JP, Hsia S, Eyde S, et al.. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023, 402:472-483. 10.1016\/S0140-6736(23)01302-8","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai T","year":"2020","unstructured":"Kawai T, Sun B, Yoshino H, et al.. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A. 2020, 117:29959-29967. 10.1073\/pnas.2014879117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena AR","year":"2021","unstructured":"Saxena AR, Gorman DN, Esquejo RM, et al.. Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nat Med. 2021, 27:1079-1087. 10.1038\/s41591-021-01391-w","journal-title":"Nat Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094646","article-title":"G protein-coupled receptor sorting to endosomes and lysosomes","volume":"48","author":"Marchese A","year":"2008","unstructured":"Marchese A, Paing MM, Temple BR, Trejo J. G protein-coupled receptor sorting to endosomes and lysosomes. Annu Rev Pharmacol Toxicol. 2008, 48:601-629. 10.1146\/annurev.pharmtox.48.113006.094646","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.56305\/001c.132255","article-title":"Current insights, advantages and challenges of small molecule glucagon-like peptide 1 receptor agonists: a scoping review","volume":"4","author":"Luna Ceron E","year":"2025","unstructured":"Luna Ceron E, Reddy SD, Kattamuri L, Muvva DM, Chozet L, Bright T. Current insights, advantages and challenges of small molecule glucagon-like peptide 1 receptor agonists: a scoping review. J Brown Hosp Med. 2025, 4:19-32. 10.56305\/001c.132255","journal-title":"J Brown Hosp Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher D","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010, 8:336-341. 10.1016\/j.ijsu.2010.02.007","journal-title":"Int J Surg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston M","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019, 10:ED000142. 10.1002\/14651858.ED000142","journal-title":"Cochrane Database Syst Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1373","article-title":"MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta","volume":"10","author":"Owen RK","year":"2019","unstructured":"Owen RK, Bradbury N, Xin Y, Cooper N, Sutton A. MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Res Synth Methods. 2019, 10:569-581. 10.1002\/jrsm.1373","journal-title":"Res Synth Methods"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15150","article-title":"Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes","volume":"25","author":"Pratt E","year":"2023","unstructured":"Pratt E, Ma X, Liu R, et al.. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes Obes Metab. 2023, 25:2642-2649. 10.1111\/dom.15150","journal-title":"Diabetes Obes Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505669","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes","volume":"393","author":"Rosenstock J","year":"2025","unstructured":"Rosenstock J, Hsia S, Nevarez Ruiz L, et al.. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025, 393:1065-1076. 10.1056\/NEJMoa2505669","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70022","article-title":"Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of \u03b2-cell function and insulin sensitivity in type 2 diabetes","volume":"27","author":"Rosenstock J","year":"2025","unstructured":"Rosenstock J, Robins DA, Duffin KL, et al.. Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of \u03b2-cell function and insulin sensitivity in type 2 diabetes. Diabetes Obes Metab. 2025, 27:6314-6322. 10.1111\/dom.70022","journal-title":"Diabetes Obes Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton S","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, et al.. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023, 389:877-888. 10.1056\/NEJMoa2302392","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2023","volume":"46","author":"ElSayed NA","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al.. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023, 46:S140-S157. 10.2337\/dc23-S009","journal-title":"Diabetes Care"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS- 1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock J","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al.. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS- 1): a double-blind, randomised, phase 3 trial. Lancet. 2021, 398:143-155. 10.1016\/S0140-6736(21)01324-6","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS- 4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato S","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, et al.. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS- 4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021, 398:1811-1824. 10.1016\/s0140-6736(21)02188-7","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01201-1","article-title":"Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists","volume":"402","author":"Nauck MA","year":"2023","unstructured":"Nauck MA, Horowitz M. Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists. Lancet. 2023, 402:429-431. 10.1016\/S0140-6736(23)01201-1","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.05.007","article-title":"Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches","volume":"157","author":"Brayden DJ","year":"2020","unstructured":"Brayden DJ, Hill TA, Fairlie DP, Maher S, Mrsny RJ. Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches. Adv Drug Deliv Rev. 2020, 157:2-36. 10.1016\/j.addr.2020.05.007","journal-title":"Adv Drug Deliv Rev"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0984","article-title":"Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide","volume":"40","author":"Nauck MA","year":"2017","unstructured":"Nauck MA, Frossard JL, Barkin JS, Anglin G, Hensley IE, Harper KD, Milicevic Z. Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. Diabetes Care. 2017, 40:647-654. 10.2337\/dc16-0984","journal-title":"Diabetes Care"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli C","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsb\u00f8l JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017, 5:251-260. 10.1016\/S2213-8587(17)30013-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos TD","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014, 11:202-230. 10.1900\/RDS.2014.11.202","journal-title":"Rev Diabet Stud"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2025.2480512","article-title":"Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Awad AA","year":"2025","unstructured":"Awad AA, Abdrabou AA, Mohammed F, et al.. Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025, 38:514-522. 10.1080\/08998280.2025.2480512","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2025.2456441","article-title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Abdrabou AA","year":"2025","unstructured":"Abdrabou AA, Abdelrehim AM, Bashir MN, et al.. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025, 38:291-303. 10.1080\/08998280.2025.2456441","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.93065","article-title":"Efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists for spinal fusion outcomes: a comprehensive meta-analysis","volume":"17","author":"Zahed M","year":"2025","unstructured":"Zahed M, Elmesalmi M, Al-Kharouf KF, et al.. Efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists for spinal fusion outcomes: a comprehensive meta-analysis. Cureus. 2025, 17:e93065. 10.7759\/cureus.93065","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/448231-comparative-efficacy-and-safety-of-different-orforglipron-doses-in-patients-with-type-2-diabetes-mellitus-and-obesity-a-systematic-review-and-network-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T23:56:58Z","timestamp":1769039818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/448231-comparative-efficacy-and-safety-of-different-orforglipron-doses-in-patients-with-type-2-diabetes-mellitus-and-obesity-a-systematic-review-and-network-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.102018","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}